Stocktoria
PALVELLA THERAPEUTICS, INC. PVLA
PALVELLA THERAPEUTICS, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $42.8M | $25.9M | $31.4M | $29.3M | $46.3M | $29.1M | $25.3M | $5.8M |
| R&D expense | $22.8M | $8.2M | $8.8M | $53.0M | $66.7M | $46.5M | $55.0M | $41.5M | $22.3M | $19.7M |
| Operating income | -$38.6M | -$14.1M | -$11.9M | -$43.5M | -$51.8M | -$33.9M | -$27.2M | -$30.8M | -$14.6M | -$22.8M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $164,000 | $0 | -$312,000 | $1.1M | $162,000 |
| Net income | -$41.7M | -$17.4M | $18.7M | -$33.3M | -$45.7M | -$37.2M | -$25.5M | -$26.8M | -$17.6M | -$22.8M |
| EPS (diluted) | $-3.71 | $-7.83 | $2.17 | — | $-0.71 | $-0.68 | — | — | — | — |
| Operating cash flow | -$25.0M | -$10.8M | -$13.7M | -$59.9M | -$7.7M | -$45.9M | -$52.5M | -$1.1M | $49.8M | -$14.4M |
| Free cash flow | — | — | -$13.9M | -$61.0M | -$8.6M | -$48.6M | -$54.9M | -$2.8M | $47.8M | -$14.9M |
| Cash & equivalents | $58.0M | $83.6M | $7.3M | $38.6M | $117.8M | $70.4M | $62.3M | $74.9M | $37.9M | $29.4M |
| Total assets | $59.6M | $88.2M | $7.5M | $95.5M | $153.6M | $105.0M | $141.1M | $141.3M | $103.9M | $35.1M |
| Total liabilities | $31.6M | $25.6M | $11.4M | $67.6M | $102.8M | $74.0M | $89.7M | $101.4M | $92.4M | $9.8M |
| Shareholders' equity | $28.0M | $62.6M | -$74.5M | -$93.8M | $50.8M | $31.0M | $51.4M | $39.9M | $11.5M | $25.2M |
Growth · year-over-year · Revenue CAGR 32.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | +65.3% | -17.6% | +7.1% | -36.6% | +59.0% | +15.1% | +333.5% | +98.9% |
| Net income growth | — | -193.3% | — | — | — | — | — | — | — | — |
| EPS growth | — | -460.8% | — | — | — | — | — | — | — | — |
| Free cash flow growth | — | — | — | — | — | — | — | -105.8% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.